We are live on ! Find out more
EVH icon

Evolent Health

174 hedge funds and large institutions have $585M invested in Evolent Health in 2019 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 80 increasing their positions, 45 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

361% more call options, than puts

Call options by funds: $12.1M | Put options by funds: $2.63M

78% more repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 45

2.92% more ownership

Funds ownership: 97.14%100.06% (+2.9%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

4% less capital invested

Capital invested by funds: $611M → $585M (-$26M)

5% less funds holding

Funds holding: 183174 (-9)

26% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 27

Holders
174
Holders Change
-9
Holders Change %
-4.92%
% of All Funds
3.82%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
20
Increased
80
Reduced
45
Closed
27
Calls
$12.1M
Puts
$2.63M
Net Calls
+$9.49M
Net Calls Change
+$5.29M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$48.5M +$1.3M +181,135 +3%
BlackRock
2
BlackRock
New York
$46.6M +$10.1M +1,410,997 +28%
JP Morgan Chase
3
JP Morgan Chase
New York
$45M +$10.7M +1,490,749 +31%
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$26.7M +$451K +62,915 +2%
CS
5
Credit Suisse
Switzerland
$26M +$2.61M +363,414 +11%
RP
6
Riverbridge Partners
Minnesota
$24.7M +$179K +24,929 +0.7%
BG
7
Bellevue Group
Switzerland
$21.8M +$4.85M +676,022 +29%
EAM
8
Eagle Asset Management
Florida
$21.6M +$8.25M +1,149,789 +62%
CTA
9
Carillon Tower Advisers
Florida
$20.1M +$8.38M +1,167,612 +71%
ECP
10
Elk Creek Partners
Colorado
$16.4M +$829K +115,522 +5%
Aberdeen Group
11
Aberdeen Group
United Kingdom
$16M +$233K +32,429 +1%
SAM
12
Silvercrest Asset Management
New York
$14.7M +$14.6M +2,040,585 New
FG
13
Formula Growth
Quebec, Canada
$12.5M +$4.88M +680,000 +64%
Wellington Management Group
14
Wellington Management Group
Massachusetts
$11.9M +$11.6M +1,611,205 +3,856%
SAM
15
Sectoral Asset Management
Quebec, Canada
$11.4M +$1.63M +227,400 +17%
PCM
16
Peregrine Capital Management
Minnesota
$11M +$2.91M +405,993 +36%
State Street
17
State Street
Massachusetts
$10.6M +$720K +100,323 +7%
Bank of America
18
Bank of America
North Carolina
$9.85M +$1.51M +210,670 +18%
GF
19
Gabelli Funds
New York
$8.7M +$1.29M +179,500 +17%
Northern Trust
20
Northern Trust
Illinois
$8.37M +$1.05M +146,658 +14%
Baillie Gifford & Co
21
Baillie Gifford & Co
United Kingdom
$7.79M +$83.1K +11,584 +1%
PAMU
22
Pictet Asset Management (UK)
United Kingdom
$7.32M -$165K -22,969 -2%
William Blair & Company
23
William Blair & Company
Illinois
$7.26M -$1.49M -207,917 -17%
RA
24
Royce & Associates
New York
$7.13M +$1.91M +265,811 +37%
Geode Capital Management
25
Geode Capital Management
Massachusetts
$6.7M +$343K +47,761 +5%

EVH Hedge Fund Activity: Q3 2019 in Review

174 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Evolent Health (EVH) for Q3 2019, worth a combined $585M — down 4.3% from $611M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of EVH and 20 opened new positions — a net loss of 7 holders — while 45 trimmed existing stakes and 80 added.

The largest buyer was Silvercrest Asset Management, opening a new position worth an estimated $14.6M. The largest seller was Marshall Wace, cutting an estimated $8.56M.

  • 174 institutional investors held Evolent Health (EVH) as of Q3 2019, down from 183 in Q2 2019.
  • Funds reported $585M of Evolent Health stock for Q3 2019, down 4.3% quarter-over-quarter.
  • 20 funds opened new Evolent Health positions in Q3 2019 and 27 closed out, a net change of -7 holders.
  • The largest Evolent Health buyer in Q3 2019 was Silvercrest Asset Management, an estimated $14.6M added.
  • The largest Evolent Health seller in Q3 2019 was Marshall Wace, an estimated $8.56M sold.

Based on aggregated 13F filings for Q3 2019.